Travere Therapeutics, Inc.
Clinical trials sponsored by Travere Therapeutics, Inc., explained in plain language.
Biopharmaceutical company developing treatments for rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for transplant patients: drug targets kidney protein leak Results expected Mar 2027 (estimated)
- New hope for kids with rare kidney diseases: drug trial aims to cut protein leak Results expected Mar 2027 (estimated)
- Can a Lab-Made enzyme tame a rare genetic disorder? Results expected Jul 2027 (estimated)
- New shot could tame rare metabolic disease Results expected Aug 2027 (estimated)
-
New kidney drug shows promise in FSGS trial
Disease control CompletedThis Phase 3 trial tested whether sparsentan, a drug that blocks two pathways involved in kidney damage, can better protect kidney function than the standard treatment irbesartan in people with focal segmental glomerulosclerosis (FSGS). The study enrolled 371 adults and children …
Phase 3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug cocktail shows promise for slowing kidney disease
Disease control CompletedThis study tested whether adding sparsentan to a standard SGLT2 inhibitor can better protect kidneys in people with IgA nephropathy, a disease that can lead to kidney failure. 48 adults who were already on stable doses of both a blood pressure drug and an SGLT2 inhibitor took spa…
Phase 2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Mapping homocystinuria: how does this rare metabolic disorder unfold over a lifetime?
Knowledge-focused CompletedResearchers are following 110 people aged 1 to 65 who have homocystinuria caused by a missing or faulty CBS enzyme. The study observes how the condition changes over time under standard care, without testing any new treatment. Participants give blood samples, complete quality-of-…
Sponsor: Travere Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC